(Q36811466)

16 August 2017

1 reference

title

Emerging drug treatments for solid tumours (English)

1 reference

16 August 2017

J H Schellens

1

1 reference

16 August 2017

L C Pronk

series ordinal

2

1 reference

16 August 2017

J Verweij

series ordinal

3

1 reference

16 August 2017

publication date

1 January 1996

1 reference

16 August 2017

1 reference

16 August 2017

volume

51

1 reference

16 August 2017

issue

1

1 reference

16 August 2017

page(s)

45-72

1 reference

Docetaxel (Taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG)

16 August 2017

cites work

1 reference

12 December 2020

Topoisomerase I and II activity in human breast, cervix, lung and colon cancer

1 reference

12 December 2020

Taxol: a novel investigational antimicrotubule agent

1 reference

12 December 2020

Relationships between the structure of taxol analogs and their antimitotic activity

1 reference

12 December 2020

Interaction of ionizing radiation with the topoisomerase I poison camptothecin in growing V-79 and HeLa cells.

1 reference

12 December 2020

Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group

1 reference

12 December 2020

Determination of Taxotere in human plasma by a semi-automated high-performance liquid chromatographic method

1 reference

12 December 2020

Induction of differentiation of cultured human and mouse myeloid leukemia cells by alkyl-lysophospholipids.

1 reference

12 December 2020

Taxol stabilizes microtubules in mouse fibroblast cells

1 reference

12 December 2020

Saturation of 2',2'-difluorodeoxycytidine 5'-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine

1 reference

12 December 2020

Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes

1 reference

12 December 2020

Synergistic cell killing by ionizing radiation and topoisomerase I inhibitor topotecan (SK&F 104864)

1 reference

12 December 2020

European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion

1 reference

12 December 2020

Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia.

1 reference

12 December 2020

Anthracycline antibiotics in cancer therapy. Focus on drug resistance

1 reference

12 December 2020

A phase I clinical, plasma, and cellular pharmacology study of gemcitabine

1 reference

12 December 2020

In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks

1 reference

12 December 2020

Evaluation of the cytotoxicity of the indoloquinone eo9 in a human colon adenocarcinoma model

1 reference

12 December 2020

Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines

1 reference

12 December 2020

Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103.

1 reference

12 December 2020

Hypocalcemia and Inhibition of Parathyroid Hormone Secretion after Administration of WR-2721 (a Radioprotective and Chemoprotective Agent)

1 reference

12 December 2020

Prevention of cisplatin neurotoxicity with an ACTH(4-9) analogue in patients with ovarian cancer

1 reference

12 December 2020

1 reference

12 December 2020

The molecular heterogeneity of protein kinase C and its implications for cellular regulation

1 reference

12 December 2020

CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer

1 reference

12 December 2020

Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor

1 reference

12 December 2020

Phase I Study of Weekly Intravenous Infusions of CPT-11, a New Derivative of Camptothecin, in the Treatment of Advanced Non-Small-Cell Lung Cancer

1 reference

12 December 2020

Effects of antimitotic agents on tubulin-nucleotide interactions

1 reference

12 December 2020

Mechanism of cross-resistance to a camptothecin analogue (CPT-11) in a human ovarian cancer cell line selected by cisplatin

1 reference

12 December 2020

Antiinvasive effect of racemic 1-O-octadecyl-2-O-methylglycero-3-phosphocholine on MO4 mouse fibrosarcoma cells in vitro.

1 reference

12 December 2020

Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group.

1 reference

12 December 2020

DNA topoisomerase poisons as antitumor drugs

1 reference

12 December 2020

Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group

1 reference

12 December 2020

Modification of cell surface carbohydrates and invasive behavior by an alkyl lysophospholipid.

1 reference

12 December 2020

Cytotoxicity and metabolism of alkyl phospholipid analogues in neoplastic cells.

1 reference

12 December 2020

Bioreductive drugs for cancer therapy: the search for tumor specificity

1 reference

12 December 2020

Relative importance of DT-diaphorase and hypoxia in the bioactivation of EO9 by human lung tumor cell lines

1 reference

12 December 2020

The protein kinase C family: heterogeneity and its implications

1 reference

12 December 2020

Docetaxel and paclitaxel inhibit DNA-adduct formation and intracellular accumulation of cisplatin in human leukocytes

1 reference

12 December 2020

Recent advances in the development of anticancer drugs that act against signalling pathways.

1 reference

12 December 2020

Phase II study of oral miltefosine in patients with squamous cell head and neck cancer

1 reference

12 December 2020

Phase I clinical and pharmacokinetic study of taxol.

1 reference

12 December 2020

Docetaxel in advanced renal carcinoma. A phase II trial of the National Cancer Institute of Canada Clinical Trials Group.

1 reference

12 December 2020

Preclinical in vivo activity of 2',2'-difluorodeoxycytidine (Gemcitabine) against human head and neck cancer

1 reference

12 December 2020

Phase I and pharmacodynamic study of taxol in refractory acute leukemias.

1 reference

12 December 2020

Membrane-interactive lipids as experimental anticancer drugs

1 reference

12 December 2020

The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics

1 reference

12 December 2020

High-performance liquid chromatographic assay for taxol in human plasma and urine and pharmacokinetics in a phase I trial

1 reference

12 December 2020

WR2721 as a modulator of cisplatin- and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach

1 reference

12 December 2020

Sequences of taxol and cisplatin: a phase I and pharmacologic study

1 reference

12 December 2020

Docetaxel (Taxotere), a novel taxoid, in the treatment of advanced colorectal carcinoma: an EORTC Early Clinical Trials Group Study

1 reference

12 December 2020

Gemcitabine: current status of phase I and II trials

1 reference

12 December 2020

Phase I trial of taxol in patients with advanced cancer

1 reference

12 December 2020

The establishment, characterization and calibration of human ovarian carcinoma xenografts for the evaluation of novel platinum anticancer drugs

1 reference

12 December 2020

Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: characterization and mechanism of resistance

1 reference

12 December 2020

Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothec in, a novel water-soluble derivative of camptothecin, against murine tumors

1 reference

12 December 2020

Antitumor activity and toxicity of cisplatin analogs

1 reference

12 December 2020

Activity of docetaxel (Taxotere) in small cell lung cancer. The Early Clinical Trials Group of the EORTC.

1 reference

12 December 2020

Preclinical activity of a new platinum analogue, lobaplatin, in cisplatin-sensitive and -resistant human testicular, ovarian, and gastric carcinoma cell lines

1 reference

12 December 2020

A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group.

1 reference

12 December 2020

DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts

1 reference

12 December 2020

Effects of CPT-11 in combination with other anti-cancer agents in culture

1 reference

12 December 2020

Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer

1 reference

12 December 2020

EO9: a novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models

1 reference

12 December 2020

Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue

1 reference

12 December 2020

Intratumoral pharmacokinetic analysis by 19F-magnetic resonance spectroscopy and cytostatic in vivo activity of gemcitabine (dFdC) in two small cell lung cancer xenografts

1 reference

12 December 2020

Phase I clinical trial of irinotecan (CPT-11), 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, and cisplatin in combination with fixed dose of vindesine in advanced non-small cell lung cancer

1 reference

12 December 2020

Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma.

1 reference

12 December 2020

Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody

1 reference

12 December 2020

Lipid activation of protein kinase C.

1 reference

12 December 2020

Phase II study of daily oral miltefosine (hexadecylphosphocholine) in advanced colorectal cancer

1 reference

12 December 2020

A phase II trial of taxol in metastatic melanoma

1 reference

12 December 2020

Topoisomerase I inhibitors: topotecan and irenotecan

1 reference

12 December 2020

Phase I and pharmacokinetic study of taxotere (RP 56976) administered as a 24-hour infusion

1 reference

12 December 2020

Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule.

1 reference

12 December 2020

Measurement of cremophor EL following taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype

1 reference

12 December 2020

Taxol: an antimitotic agent with a new mechanism of action

1 reference

12 December 2020

Potential role of oral anthracyclines in older patients with cancer

1 reference

12 December 2020

1 reference

12 December 2020

Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors

1 reference

12 December 2020

Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks.

1 reference

12 December 2020

Docetaxel (Taxotere) in advanced renal cell cancer. A phase II trial of the EORTC Early Clinical Trials Group

1 reference

12 December 2020

Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study

1 reference

12 December 2020

Effects of Taxotere and taxol on in vitro colony formation of freshly explanted human tumor cells

1 reference

12 December 2020

Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting

1 reference

12 December 2020

Phase II Trial of Taxol in Patients with Metastatic Renal Cell Carcinoma

1 reference

12 December 2020

A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group study

1 reference

12 December 2020

Preclinical activity of taxotere (RP 56976, NSC 628503) against freshly explanted clonogenic human tumour cells: comparison with taxol and conventional antineoplastic agents.

1 reference

12 December 2020

Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer

1 reference

12 December 2020

Preclinical and phase I trials of topoisomerase I inhibitors

1 reference

12 December 2020

Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro

1 reference

12 December 2020

Can WR-2721 be improved upon?

1 reference

12 December 2020

In vitro evaluation of platinum, titanium and ruthenium metal complexes in cisplatin-sensitive and -resistant rat ovarian tumors

1 reference

12 December 2020

Inhibition of experimental metastasis and cell adhesion of B16F1 melanoma cells by inhibitors of protein kinase C.

1 reference

12 December 2020

Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea

1 reference

12 December 2020

Paclitaxel (Taxol) in heavily pretreated ovarian cancer: antitumor activity and complications

1 reference

12 December 2020

Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor

1 reference

12 December 2020

Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) in previously treated ovarian cancer patients

1 reference

12 December 2020

The current status of camptothecin analogues as antitumor agents

1 reference

12 December 2020

Characterization of camptothecin-resistant chinese hamster lung cells

1 reference

12 December 2020

A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer

1 reference

12 December 2020

Contrasting molecular cytotoxic mechanisms of mitomycin C and its two analogs, BMY 25282 and BMY 25067, in isolated rat hepatocytes.

1 reference

12 December 2020

Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity

1 reference

12 December 2020

Chemosensitivity to the indoloquinone EO9 is correlated with DT-diaphorase activity and its gene expression

1 reference

12 December 2020

Cytoskeleton-disrupting drugs enhance effect of growth factors and hormones on initiation of DNA synthesis

1 reference

12 December 2020

Phase II evaluation of Taxol in advanced head and neck cancer: an Eastern Cooperative Oncology group trial

1 reference

12 December 2020

Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea

1 reference

12 December 2020

A phase II study of taxol in patients with malignant melanoma

1 reference

12 December 2020

Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans

1 reference

12 December 2020

Increases in leucocyte and platelet counts induced by the alkyl phospholipid hexadecylphosphocholine

1 reference

12 December 2020

Clinical and preclinical activity of 2',2'-difluorodeoxycytidine (gemcitabine).

1 reference

12 December 2020

In-vitro schedule-dependency of eo9 and miltefosine in comparison to standard drugs in colon-cancer cells

1 reference

12 December 2020

Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study

1 reference

12 December 2020

Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11

1 reference

12 December 2020

Elevated level of nuclear protein kinase C in multidrug-resistant MCF-7 human breast carcinoma cells

1 reference

12 December 2020

Taxol metabolism by human liver microsomes: identification of cytochrome P450 isozymes involved in its biotransformation

1 reference

12 December 2020

1 reference

12 December 2020

Phase II study of topotecan in metastatic non-small-cell lung cancer

1 reference

12 December 2020

Phase I study of topotecan for pediatric patients with malignant solid tumors

1 reference

12 December 2020

Phase II study of miltefosine (hexadecylphosphocholine) in advanced soft tissue sarcomas of the adult--an EORTC Soft Tissue and Bone Sarcoma Group Study

1 reference

12 December 2020

A randomized trial of carboplatin versus iproplatin in untreated advanced ovarian cancer.

1 reference

12 December 2020

Synthesis of water-soluble (aminoalkyl)camptothecin analogs: inhibition of topoisomerase I and antitumor activity

1 reference

12 December 2020

Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study.

1 reference

12 December 2020

A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer

1 reference

12 December 2020

A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group.

1 reference

12 December 2020

Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group Results

1 reference

12 December 2020

Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion

1 reference

12 December 2020

Towards selective pharmacological modulation of protein kinase C--opportunities for the development of novel antineoplastic agents

1 reference

12 December 2020

Nonenzymatic reductive activation of 7-N-((2-([2-(gamma-L-glutamylamino)ethyl]dithio)ethyl))mitomycin C by thiol molecules: a novel mitomycin C derivative effective on mitomycin C-resistant tumor cells.

1 reference

12 December 2020

Phase II Trial of Taxol, an Active Drug in the Treatment of Metastatic Breast Cancer

1 reference

12 December 2020

Ormaplatin sensitivity/resistance in human ovarian cancer cells made resistant to cisplatin.

1 reference

12 December 2020

Surface modulation in cell recognition and cell growth

1 reference

12 December 2020

Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma

1 reference

12 December 2020

A phase I study of 1,2-diamminomethyl-cyclobutane-platinum (II)-lactate (D-19466; lobaplatin) administered daily for 5 days.

1 reference

12 December 2020

Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine).

1 reference

12 December 2020

Idarubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer

1 reference

12 December 2020

Cytotoxic activity of 7-N-(2-((2-(-gamma-L-glutamylamino)- ethyl)dithio)ethyl)-mitomycin C and metabolites in cell lines with different resistance patterns

1 reference

12 December 2020

Coping with toxicities of docetaxel (Taxotere)

1 reference

12 December 2020

Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in murine and human tumor models

1 reference

12 December 2020

Protein kinase C: a novel target for inhibiting gastric cancer cell invasion

1 reference

12 December 2020

Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind

1 reference

12 December 2020

Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine (Gemcitabine) administration in leukemia

1 reference

12 December 2020

Clinical trials of WR-2721 prior to alkylating agent chemotherapy and radiotherapy

1 reference

12 December 2020

Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen

1 reference

12 December 2020

Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. EORTC Soft Tissue and Bone Sarcoma Group

1 reference

12 December 2020

Evidence that microtubule depolymerization early in the cell cycle is sufficient to initiate DNA synthesis

1 reference

12 December 2020

Pharmacokinetic and biotransformation studies of ormaplatin in conjunction with a phase I clinical trial.

1 reference

12 December 2020

Effects of Taxotere on murine and human tumor cell lines

1 reference

12 December 2020

Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug E09.

1 reference

12 December 2020

Unusually marked hypoxic sensitization to indoloquinone EO9 and mitomycin C in a human colon-tumour cell line that lacks DT-diaphorase activity.

1 reference

12 December 2020

Sensitivity to novel platinum compounds of panels of human lung cancer cell lines with acquired and inherent resistance to cisplatin

1 reference

12 December 2020

Phase I Study and Pharmacokinetics of CPT-11 With 5-Day Continuous Infusion

1 reference

12 December 2020

Camptothecins: from bench research to hospital wards.

1 reference

12 December 2020

Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion

1 reference

12 December 2020

Mechanism of action of taxol

1 reference

12 December 2020

Topotecan in colorectal cancer: a phase II study of the EORTC early clinical trials group

1 reference

12 December 2020

Phase I study of WR-2721 and carboplatin

1 reference

12 December 2020

Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer

1 reference

12 December 2020

Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly

1 reference

12 December 2020

Docetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC Early Clinical Trials Group

1 reference

12 December 2020

Quantitative and qualitative aspects of topoisomerase I and II alpha and beta in untreated and platinum/cyclophosphamide treated malignant ovarian tumors

1 reference

12 December 2020

Mechanism of differential sensitivity of human bladder cancer cells to mitomycin C and its analogue

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer

1 reference

12 December 2020

Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia

1 reference

12 December 2020

Activation of the trans geometry in platinum antitumor complexes: a survey of the cytotoxicity of trans complexes containing planar ligands in murine L1210 and human tumor panels and studies on their mechanism of action

1 reference

12 December 2020

Phase I study of taxol administered as a short i.v. infusion daily for 5 days.

1 reference

12 December 2020

Selective destruction of human leukemic cells by alkyl-lysophospholipids

1 reference

12 December 2020

A new mammalian DNA topoisomerase I poison Hoechst 33342: cytotoxicity and drug resistance in human cell cultures.

1 reference

12 December 2020

Phase I trial of Taxotere: five-day schedule

1 reference

12 December 2020

Phase II trial of docetaxel (Taxotere) in metastatic colorectal carcinoma

1 reference

12 December 2020

A phase I trial of taxol given by a 6-hour intravenous infusion

1 reference

12 December 2020

Activity of intoplicine (RP60475), a new DNA topoisomerase I and II inhibitor, against human tumor colony-forming units in vitro.

1 reference

12 December 2020

Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer

1 reference

12 December 2020

Alkyl-lysophospholipid induced suppression of human lymphocyte response to mitogens and selective killing of lymphoblasts

1 reference

12 December 2020

Randomised phase II trial of carboplatin and iproplatin in advanced urothelial cancer

1 reference

12 December 2020

Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms

1 reference

12 December 2020

A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days

1 reference

12 December 2020

10.2165/00003495-199651010-00005

Identifiers

DOI

1 reference

Dimensions Publication ID

16 August 2017

1032605290

0 references

1 reference